🔴 BioXcel Therapeutics is trading 5.94% down today after second-quarter EPS and revenue missed estimates

BioXcel Therapeutics is trading 5.94% down now at $0.84 after its August 17, 2026, second-quarter results missed analyst expectations.

• EPS was -$0.490 versus -$0.423 estimated; revenue was $182K versus $403.32K expected.
• The company reported $13.8 million in cash and $17.9 million in first-half operating cash use, intensifying liquidity concerns.
• The decline follows a 25.21% drop on August 17.